Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/20/2014)... Aug. 20, 2014 The National Necrotizing Fasciitis Foundation ... has been successfully treated for a life threatening form ... Anibal R. Gauto , Medical Director of Inpatient Wound Care ... Center in Rancho Mirage, California . ... Dr. John Crew at Seton Hospital in ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and Markets ... of Pralmorelin" report to their offering. ... comprehensive data on Pralmorelin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 As ... use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... that two U.S. Senators from New York are urging ... a recall of the devices. In a letter dated ... Democrats, also implored the agency to seriously consider the ...
(Date:8/20/2014)... the amygdala stimulates stress responses in adults, researchers ... have found that the amygdala has an inhibitory ... of nonhuman primates. , The results are published ... , The amygdala is a region of the ... threatening situations and learning about threats. Alterations in ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... years, the Tower of London has had an iconic status ... it is facing a major pollution threat. ... cars and trucks, and the discoloration is most noticeable at ... William the Conqueror in 1078, says study co-author Peter Brimblecombe, ...
... is of the view that glycerin, a by-product of bio-diesel, ... , ,In his study, Monty Kerley, a professor of ... effectiveness of glycerin as cattle feed. ,Through ... from various breeds to determine if bio-leftovers provide a healthy ...
... died of anthrax in Orissa's tribal dominated Koraput district, ... last two days, health officials said Friday. ... Jani, 35, of Padiguda village under Semliguda block in ... disease reportedly after consuming cattle meat. ,K.H. ...
... reinstated as executive director of the Escorts hospital here ... the hospital announced Saturday. ,Fortis Healthcare, which ... Institute and Research Centre (EHIRC), Saturday withdrew the police ... sacking last week as a "result of misunderstanding". ...
... the Department of Chemical Engineering makes it possible to remove ... The process is based on biosorption, which is a ... can be used to purify water from painting, tannery or ... whenever olive oil is obtained: what can we do with ...
... Results from an international multi-center Phase II clinical ... effective in treating patients with clinically active ... are refractory to immunosuppressants and/or anti-TNF agents. A ... treatment was noted in the study, using standard ...
Cached Medicine News:Health News:Study Finds Glycerin to Be a Good Source for Cattle Feed 2Health News:Naresh Trehan Reinstated as Chief of Escorts After Weeklong Row 2Health News:Olive Stones to Depollute Industrial Sewage Water 2Health News:ECP may Be Effective in Treating Crohn's Disease 2
... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
Inquire...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
Medicine Products: